02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
19:24 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Amgen to start its first CAR T trial in 1H18

Amgen Inc. (NASDAQ:AMGN) said it plans to start clinical testing of its first chimeric antigen receptor (CAR) T cell therapy this half. The trial will evaluate a single IV infusion of AMG 119 in about...